Facebook
X
LinkedIn
ForwardLiquid Biopsies in Cancer (PRO 04)
Liquid biopsy technologies, particularly circulating tumor DNA (ctDNA), are an emerging tool in precision oncology with growing relevance in radiation oncology. This activity focuses on the current and near-term clinical applications of ctDNA, including noninvasive tumor genotyping, early cancer detection, and minimal residual disease (MRD) monitoring. Expert physician-scientists present recent data that highlight the strengths, limitations, and practical considerations for using liquid biopsy in clinical workflows.
Target Audience
This activity is designed to meet the interests of radiation oncologists, radiation physicists, nurses, radiation therapists, dosimetrists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Understand the basics regarding circulating tumor DNA (ctDNA) and liquid biopsy technologies and applications.
- Understand the utility of ctDNA for noninvasive genotyping, early cancer detection, and minimal residual disease detection and monitoring.
- Simul Dinesh Parikh, MD, is employed by Lake Huron Medical Center.
- Nagendra (Bobby) S. Koneru, MD, FASTRO, is employed by FHN / Leonard Ferguson Cancer Center.
- Mudit Chowdhary, MD, is employed by Northside Hospital.
- Jona A. Hattangadi-Gluth, MD, is employed by University of California San Diego.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Meeting Steering Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.